Background: Nearly 2% of hospital intensive care unit patients are at risk of developing life threatening fungal infections. High mortality rates indicate that identification of disease causing organisms and choice of adequate medications are crucial in the therapeutic process.
Introduction
Fungi of the Candida species are responsible for life-threatening, nosocomial infections in medical Intensive Care Units (ICUs) with an incidence ranging from 0.74% to 1.9% of all patients admitted [1, 2] . Mortality associated with fungal infections in patients hospitalized in ICUs reaches 67% [3] . Most common species of Candida fungi are C. albicans, followed by C. glabrata [2] . Known risk factors that predispose to candidiasis are: trauma, immunosuppression, prolonged hospital stay, diabetes, mechanical ventilation, urinary tract catheterization, and central venous catheterization [4] . Fungal infections in medical ICUs are highly resistant to antifungal therapy [5] , thus early initiation of adequate treatment is crucial for the patients' survival.
The epidemiology of fungal infections changes over time [6] . Therefore it is important to verify the incidence of key Candida species every decade providing an update on epidemiology and susceptibility of strains to antifungal medications.
The aim of this study is to assess the risk factors related to fatal therapy outcome in patients infected with pathogenic fungi and describe susceptibility of specific strains to antimycotics. We also try to provide a profile of fungal infections in medical ICU setting.
Methods

Subjects and experimental protocol
Patient histories collected between 2007 and 2010 from medical ICUs with positive fungal infection were utilized in this research. All investigators had access to data and proofed their accuracy throughout this retrospective study, conducted at Poznań Regional Hospital. An algorithm describing the design of this study is illustrated in figure 1 .
The database gathered information on: 1) diagnosis given by the mycology lab based on samples acquired in the medical ICU; 2) patient age and gender; 3) medical procedures that the patient underwent: urinary and central venous catheterization, mechanical ventilation, renal replacement therapy, parenteral nutrition, multiple invasive procedures, wide spectrum antibiotic therapy; 4) comorbid conditions: renal insufficiency, diabetes mellitus, acute pancreatitis, cirrhosis, adult respiratory distress syndrome (ARDS), neoplasms, HIV and cachexia.
The diagnosis of clinical samples was performed by the trained staff of the mycology department, and consisted of direct microscopic examination and species identification using Integral System Yeasts Plus, which allows for simultaneous antifungal susceptibility testing. The system uses a panel of 24 wells inoculated with a cell suspension previously incubated for 48 hours at 36
• C. Growing yeast assimilated the specific sugars present in each well allowing their identification. The following antimycotics were used in antifungal susceptibility tests: 5-flucytosine, amphotericin B, miconazole, ketoconazole, itraconazole, fluconazole and caspofungin.
Formation of the study groups
We formed study groups according to the mycological diagnosis ( Fig. 2) The mixed group was composed of rare species: C. parapsilosis, C. lusitaniae, C. kefyr, C. sphaerica and C. lipolytica. Age groups were formed according to patients' age: 18-39, 40-59, 60-79 and 80 years of age and above.
Statistical analyses
Incidence of chronic conditions associated with each group was calculated. Factors associated with increased mortality of ICU patients infected with fungi were described using either the Chi squared test with or without Yates' continuity correction or Fisher exact test where adequate. The data set was analyzed in R statistical software [7] . Wherever the term 'statistical significance' is used it refers to the test's p-value of <0.05. Considering the nature of this analysis there was no control sample. Tracheal aspirate culture -routinely performed in patients undergoing respiratory therapy allowed for the recognition of most strains, but mixed group yeast-like fungi were mainly isolated from urine (as shown in table 4).
The mixed Candida group patients showed the highest relative frequency of deaths, but this observation was not statistically significant. Nearly all examined patients underwent central venous catheterization, urinary tract catheterization and were parenterally nutritioned. It is worth mentioning that patients with concomitant diabetes were more frequently diagnosed with C. glabrata infection than any other genus (p = 0.0012). Patients infected with C. krusei were more often diagnosed with renal insufficiency (p = 0.0156), cirrhosis (p = 0.0024) and underwent renal replacement therapy than other groups (p = 0.0487). The results of Candida group comparisons are summarised in table 5.
When we investigated which procedures and conditions are linked with higher death rates, we found that renal and hepatic insufficiency were significantly more often connected with fatal therapy outcome. Also being above 80 years of age, and diabetic resulted in increased death risk compared with patients who lacked those factors. Wide spectrum antibiotic therapy during the ICU stay was linked to a lower death rate. The significance of those comparisons are summarized in table 6 and figure 3 illustrates their odds ratios.
C. albicans strains were the most resistant against antimycotics, and C. glabrata seemed to be susceptible to nearly all antimycotic drugs. Most of the strains were resistant to fluconazole. Treatment with Amphotericin B most often seemed to stop colony growth in vitro. Caspofungin was used in 15 C. albicans and 10 C. glabrata cases and showed to be effective in 92% of strains. Antimycotic drug susceptibility comparison can be seen in figure 2.
Discussion
Our data show a marked shift in Candida species distribution over the last 10 years. We have identified C. albicans, C. glabrata, C. tropicalis and C. krusei to be the most important pathogens. There are many reports that support the finding of C. albicans being the most common pathogen followed by C. glabrata and C. tropicalis [8, 9].
C. glabrata increases in numbers and is linked to diabetes
When we compared the incidence of fungal species to a previous study conducted in this very same ICU between the years of 1996-2000 [10], we noticed that although C. albicans and C. glabrata were still the most frequently occuring pathogens, there was a decline in the number of C. albicans relative to the increase of C. glabrata. Trick et al. also observed this phenomenon [11] . The growing incidence of C. glabrata appears to depend on patient age and the prophylactic use of fluconazole [9, 12].
We observed a higher incidence of C. glabrata infections in patients suffering from diabetes mellitus. Such findings have also been reported by Segireddy et al. and Harris et al. [13, 14] . It is known that C. glabrata has lower virulence compared to C. albicans. This fact may explain why humans lack specific host defense mechanisms against this commensal microorganism. This fungus, once acquired, may be carried asymptomatically over a prolonged period of time. Diabetic patients have an impaired immune system; hence they are more susceptible to C. glabrata infections, contrary to a resistant, healthy population [11] . This observation may be further explained by the fact that C. glabrata is more often diagnosed in the diabetic patient population, which itself grows in number each year, with an annual increment of 24.000 cases for Poland as estimated by Shaw et al. [15] .
Emergence of previously uncommon species
We observed previously uncommon species: C. krusei and C. lusitaniae. C. krusei along with C. parapsillosis, C. kefyr and C. guilliermondii are rarely isolated Candida species, though they are thought to be less virulent. The incidence of C. krusei has significantly increased in the last few decades [16] . Some authors try to explain this phenomenon by the fact that fluconazole prophylaxis is widely applied [9, 17, 18]. C. krusei, like other less common Candida species, are often resistant to azole antifungal drugs, thus a widespread fluconazole prophylaxis in ICU patients may be the cause for a sudden emergence of C. krusei strains [16] . Also C. lusitaniae could occur more frequently, due to the acquisition of multidrug resistance [19] .
C. krusei and concomitant diseases According to our research, there is a link between C. krusei infection and cirrhosis. We have shown that patients with cirrhosis were more frequent in the C. krusei infected group. Renal insufficiency was not significantly associated with C. krusei infections, but this may be due to low number of C. krusei infections described in this study. This finding was also observed by Choi et al. [20] and Ortega et al. [21] . A theoretical model in which C. krusei would predominantly infect single-organinsufficient patients more than any other Candida species is not presently known. Our study describes the novel finding that there is higher incidence of C. krusei in the hepatic insufficiency group, yet undoubtedly more studies need to be done to support this. Choi et al. reported approximately 26% of their patients (5 out of 19) to have both C. krusei infecion and renal insufficiency [20] . These data are in parallel with ours.
Fatal therapy outcomes
We also have found that not only diabetes mellitus comorbidity contributed to the fatal therapy outcome, but chronic renal and hepatic insufficiency did as well. These findings are consistent with data from research regarding organ transplant recipients with candidemia [22].
Other factors, such as patient age and sex also have a strong impact on the result of treatment. We came to conclusion that male patients, as well as older patients with fungal infections had a poorer prognosis, in comparison to groups involving young and female patients. Interestingly, there is a strong link between Candida species and the patient's age. Neonates and infants are predominantly infected with C. parapsilosis, old patients with C. glabrata, while C. albicans is the most prominent species in young adults with a gradual decline towards older age groups [23] .
Antibiotic Suscetibility Testing (AST)
One of our goals was to describe the susceptibility of species to certain antifungal drugs. We observed that C. krusei is resistant to fluconazole, a finding previously described in other studies. Orozco, who investigated the reason for this phenomenon, came to the conclusion that 14-α demetylase of C. krusei cells, which is a target enzyme for fluconazole, has 14 times lower susceptibility to inhibition by fluconazole than this very same enzyme in C. albicans species 
